Literature DB >> 31737507

KEYNOTE-021 cohorts D and H suggest modest benefit in combining ipilimumab with pembrolizumab in second-line or later advanced non-small cell lung cancer treatment.

Amy Lauren Cummings1, Kate M Santoso2, Jonathan W Goldman1.   

Abstract

Entities:  

Year:  2019        PMID： 31737507      PMCID： PMC6835110          DOI： 10.21037/tlcr.2019.08.11

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  12 in total

1.  Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.

Authors:  Matthew D Hellmann; Tudor-Eliade Ciuleanu; Adam Pluzanski; Jong Seok Lee; Gregory A Otterson; Clarisse Audigier-Valette; Elisa Minenza; Helena Linardou; Sjaak Burgers; Pamela Salman; Hossein Borghaei; Suresh S Ramalingam; Julie Brahmer; Martin Reck; Kenneth J O'Byrne; William J Geese; George Green; Han Chang; Joseph Szustakowski; Prabhu Bhagavatheeswaran; Diane Healey; Yali Fu; Faith Nathan; Luis Paz-Ares
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

2.  Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H.

Authors:  Matthew A Gubens; Lecia V Sequist; James P Stevenson; Steven F Powell; Liza C Villaruz; Shirish M Gadgeel; Corey J Langer; Amita Patnaik; Hossein Borghaei; Shadia I Jalal; Joseph Fiore; Sanatan Saraf; Harry Raftopoulos; Leena Gandhi
Journal:  Lung Cancer       Date:  2018-12-17       Impact factor: 5.705

3.  Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.

Authors:  Matthew D Hellmann; Naiyer A Rizvi; Jonathan W Goldman; Scott N Gettinger; Hossein Borghaei; Julie R Brahmer; Neal E Ready; David E Gerber; Laura Q Chow; Rosalyn A Juergens; Frances A Shepherd; Scott A Laurie; William J Geese; Shruti Agrawal; Tina C Young; Xuemei Li; Scott J Antonia
Journal:  Lancet Oncol       Date:  2016-12-05       Impact factor: 41.316

4.  Pembrolizumab for the treatment of non-small-cell lung cancer.

Authors:  Edward B Garon; Naiyer A Rizvi; Rina Hui; Natasha Leighl; Ani S Balmanoukian; Joseph Paul Eder; Amita Patnaik; Charu Aggarwal; Matthew Gubens; Leora Horn; Enric Carcereny; Myung-Ju Ahn; Enriqueta Felip; Jong-Seok Lee; Matthew D Hellmann; Omid Hamid; Jonathan W Goldman; Jean-Charles Soria; Marisa Dolled-Filhart; Ruth Z Rutledge; Jin Zhang; Jared K Lunceford; Reshma Rangwala; Gregory M Lubiniecki; Charlotte Roach; Kenneth Emancipator; Leena Gandhi
Journal:  N Engl J Med       Date:  2015-04-19       Impact factor: 91.245

5.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

Authors:  Roy S Herbst; Paul Baas; Dong-Wan Kim; Enriqueta Felip; José L Pérez-Gracia; Ji-Youn Han; Julian Molina; Joo-Hang Kim; Catherine Dubos Arvis; Myung-Ju Ahn; Margarita Majem; Mary J Fidler; Gilberto de Castro; Marcelo Garrido; Gregory M Lubiniecki; Yue Shentu; Ellie Im; Marisa Dolled-Filhart; Edward B Garon
Journal:  Lancet       Date:  2015-12-19       Impact factor: 79.321

6.  Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.

Authors:  Scott Antonia; Sarah B Goldberg; Ani Balmanoukian; Jamie E Chaft; Rachel E Sanborn; Ashok Gupta; Rajesh Narwal; Keith Steele; Yu Gu; Joyson J Karakunnel; Naiyer A Rizvi
Journal:  Lancet Oncol       Date:  2016-02-06       Impact factor: 41.316

7.  EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.

Authors:  Justin F Gainor; Alice T Shaw; Lecia V Sequist; Xiujun Fu; Christopher G Azzoli; Zofia Piotrowska; Tiffany G Huynh; Ling Zhao; Linnea Fulton; Katherine R Schultz; Emily Howe; Anna F Farago; Ryan J Sullivan; James R Stone; Subba Digumarthy; Teresa Moran; Aaron N Hata; Yukako Yagi; Beow Y Yeap; Jeffrey A Engelman; Mari Mino-Kenudson
Journal:  Clin Cancer Res       Date:  2016-05-25       Impact factor: 12.531

8.  Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration.

Authors:  Talal Hilal; Mohamad Bassam Sonbol; Vinay Prasad
Journal:  JAMA Oncol       Date:  2019-06-01       Impact factor: 31.777

9.  First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.

Authors:  Neal Ready; Matthew D Hellmann; Mark M Awad; Gregory A Otterson; Martin Gutierrez; Justin F Gainor; Hossein Borghaei; Jacques Jolivet; Leora Horn; Mihaela Mates; Julie Brahmer; Ian Rabinowitz; Pavan S Reddy; Jason Chesney; James Orcutt; David R Spigel; Martin Reck; Kenneth John O'Byrne; Luis Paz-Ares; Wenhua Hu; Kim Zerba; Xuemei Li; Brian Lestini; William J Geese; Joseph D Szustakowski; George Green; Han Chang; Suresh S Ramalingam
Journal:  J Clin Oncol       Date:  2019-02-20       Impact factor: 44.544

Review 10.  CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition.

Authors:  Elizabeth I Buchbinder; Anupam Desai
Journal:  Am J Clin Oncol       Date:  2016-02       Impact factor: 2.339
View more
  3 in total

1.  Microenvironment characterization and multi-omics signatures related to prognosis and immunotherapy response of hepatocellular carcinoma.

Authors:  Furong Liu; Lu Qin; Zhibin Liao; Jia Song; Chaoyi Yuan; Yachong Liu; Yu Wang; Heze Xu; Qiaofeng Zhang; Youliang Pei; Hongwei Zhang; Yonglong Pan; Xiaoping Chen; Zhanguo Zhang; Wanguang Zhang; Bixiang Zhang
Journal:  Exp Hematol Oncol       Date:  2020-05-25

2.  Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.

Authors:  Bi-Cheng Wang; Bo-Ya Xiao; Peng-Cheng Li; Bo-Hua Kuang; Wang-Bing Chen; Pin-Dong Li; Guo-He Lin; Quentin Liu
Journal:  J Oncol       Date:  2020-09-29       Impact factor: 4.375

3.  Efficacy of Camrelizumab in Advanced Non-Small-Cell Lung Cancer and Prognostic Analysis of Different PET/CT Features.

Authors:  Jinhai Zou; Chunying Li; Yu Han; Yu Xing; Yingying Zhan; Chao Zuo; Xinyue Ren; Rongge Xing; Nan Zhang
Journal:  J Oncol       Date:  2022-03-25       Impact factor: 4.375
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.